NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma—opportunities for therapy

References

• Swerdlow SC, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th rev ed. Lyon: IARC Press; 2017.
   Google Scholar
• Florindez JA, Alderuccio JP, Reis IM, et al. Splenic marginal zone lymphoma: a US population-based survival analysis (1999–2016). Cancer. 2020;126:4706–4716.
   PubMed Web of Science ®Google Scholar
• Alderuccio JP, Lossos IS. Prognostic factors and risk of transformation in marginal zone lymphoma. Ann Lymphoma. 2020;4:6.
   Google Scholar
• de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol. 2008;6(4):451–458.
   PubMed Web of Science ®Google Scholar
• Peveling-Oberhag J, Crisman G, Schmidt A, et al. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia. 2012;26(7):1654–1662.
   PubMed Web of Science ®Google Scholar
• Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209(9):1537–1551.
   PubMed Web of Science ®Google Scholar
• Spina V, Mensah A, Arribas AJ. Biology of splenic and nodal marginal zone lymphomas. Ann Lymphoma. 2021;5:6.
   Google Scholar
• Watkins AJ, Hamoudi RA, Zeng N, et al. An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma. PLoS One. 2012;7(9):e44997.
   PubMed Web of Science ®Google Scholar
• Fresquet V, Robles EF, Parker A, et al. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma. Br J Haematol. 2012;158(6):712–726.
   PubMed Web of Science ®Google Scholar
• Jaramillo Oquendo C, Parker H, Oscier D, et al. Systematic review of somatic mutations in splenic marginal zone lymphoma. Sci Rep. 2019;9(1):10444.
   PubMedGoogle Scholar
• Chiang MY, Radojcic V, Maillard I. Oncogenic notch signaling in T-cell and B-cell lymphoproliferative disorders. Curr Opin Hematol. 2016;23(4):362–370.
   PubMed Web of Science ®Google Scholar
• Arruga F, Vaisitti T, Deaglio S. The NOTCH pathway and its mutations in mature B cell malignancies. Front Oncol. 2018;8:550.
   PubMed Web of Science ®Google Scholar
• Lue JK, O’Connor OA, Bertoni F. Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond. Ann Lymphoma. 2020;4:7.
   PubMedGoogle Scholar
• Raya A, Kawakami Y, Rodríguez-Esteban C, et al. Notch activity acts as a sensor for extracellular calcium during vertebrate left-right determination. Nature. 2004;427(6970):121–128.
   PubMed Web of Science ®Google Scholar
• Radojcic V, Maillard I. A jagged road to lymphoma aggressiveness. Cancer Cell. 2014;25(3):261–263.
   PubMed Web of Science ®Google Scholar
• Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269–271.
   PubMed Web of Science ®Google Scholar
• Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678–689.
   PubMed Web of Science ®Google Scholar
• Selkoe D, Kopan R. Notch and presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci. 2003;26:565–597.
   PubMed Web of Science ®Google Scholar
• Ayaz F, Osborne BA. Non-canonical notch signaling in cancer and immunity. Front Oncol. 2014;4:345.
   PubMedGoogle Scholar
• Nam Y, Weng AP, Aster JC, et al. Structural requirements for assembly of the CSL.intracellular Notch1.Mastermind-like 1 transcriptional activation complex. J Biol Chem. 2003;278(23):21232–21239.
   PubMed Web of Science ®Google Scholar
• Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66(4):649–661.
   PubMed Web of Science ®Google Scholar
• Pear WS, Aster JC, Scott ML, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated notch alleles. J Exp Med. 1996;183(5):2283–2291.
   PubMed Web of Science ®Google Scholar
• Talora C, Sgroi DC, Crum CP, et al. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev. 2002;16(17):2252–2263.
   PubMed Web of Science ®Google Scholar
• Chu J, Jeffries S, Norton JE, et al. Repression of activator protein-1-mediated transcriptional activation by the notch-1 intracellular domain. J Biol Chem. 2002;277(9):7587–7597.
   PubMed Web of Science ®Google Scholar
• Sorrentino C, Cuneo A, Roti G. Therapeutic targeting of notch signaling pathway in hematological malignancies. Mediterr J Hematol Infect Dis. 2019;11(1):e2019037.
   PubMedGoogle Scholar
• Radtke F, MacDonald HR, Tacchini-Cottier F. Regulation of innate and adaptive immunity by notch. Nat Rev Immunol. 2013;13(6):427–437.
   PubMed Web of Science ®Google Scholar
• Saito T, Chiba S, Ichikawa M, et al. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity. 2003;18(5):675–685.
   PubMed Web of Science ®Google Scholar
• Meurette O, Mehlen P. Notch signaling in the tumor microenvironment. Cancer Cell. 2018;34(4):536–548.
   PubMed Web of Science ®Google Scholar
• Witt CM, Won WJ, Hurez V, et al. Notch2 haploinsufficiency results in diminished B1 B cells and a severe reduction in marginal zone B cells. J Immunol. 2003;171(6):2783–2788.
   PubMed Web of Science ®Google Scholar
• Hernandez Tejada FN, Galvez Silva JR, Zweidler-McKay PA. The challenge of targeting notch in hematologic malignancies. Front Pediatr. 2014;2:54.
   PubMed Web of Science ®Google Scholar
• Tanigaki K, Han H, Yamamoto N, et al. Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol. 2002;3(5):443–450.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Baldoni S, Rosati E, et al. A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol. 2009;146(6):689–691.
   PubMed Web of Science ®Google Scholar
• Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014;28(1):108–117.
   PubMed Web of Science ®Google Scholar
• Karube K, Martínez D, Royo C, et al. Recurrent mutations of NOTCH genes in follicular lymphoma identify a distinctive subset of tumours. J Pathol. 2014;234(3):423–430.
   PubMed Web of Science ®Google Scholar
• O'Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204(8):1813–1824.
   PubMed Web of Science ®Google Scholar
• Schwarzer R, Dörken B, Jundt F. Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia. 2012;26(4):806–813.
   PubMed Web of Science ®Google Scholar
• Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389–1401.
   PubMed Web of Science ®Google Scholar
• Lobry C, Oh P, Mansour MR, et al. Notch signaling: switching an oncogene to a tumor suppressor. Blood. 2014;123(16):2451–2459.,
   PubMed Web of Science ®Google Scholar
• Lobry C, Ntziachristos P, Ndiaye-Lobry D, et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med. 2013;210(2):301–319.
   PubMed Web of Science ®Google Scholar
• Kannan S, Fang W, Song G, et al. Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression. Blood. 2011;117(10):2891–2900.
   PubMed Web of Science ®Google Scholar
• Majumder S, Crabtree JS, Golde TE, et al. Targeting notch in oncology: the path forward. Nat Rev Drug Discov. 2021;20(2):125–144.
   PubMed Web of Science ®Google Scholar
• Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a group for research in adult acute lymphoblastic leukemia study. J Clin Oncol. 2013;31(34):4333–4342.
   PubMed Web of Science ®Google Scholar
• Witkowski MT, Cimmino L, Hu Y, et al. Activated notch counteracts Ikaros tumor suppression in mouse and human T-cell acute lymphoblastic leukemia. Leukemia. 2015;29(6):1301–1311.
   PubMed Web of Science ®Google Scholar
• Onaindia A, Medeiros LJ, Patel KP. Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod Pathol. 2017;30(10):1338–1366.
   PubMed Web of Science ®Google Scholar
• Aydin S, Rossi D, Bergui L, et al. CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood. 2008;111(12):5646–5653.
   PubMed Web of Science ®Google Scholar
• Thomas M, Calamito M, Srivastava B, et al. Notch activity synergizes with B-cell-receptor and CD40 signaling to enhance B-cell activation. Blood. 2007;109(8):3342–3350.
   PubMed Web of Science ®Google Scholar
• Cao Z, Ding BS, Guo P, et al. Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer Cell. 2014;25(3):350–365.
   PubMed Web of Science ®Google Scholar
• Gragnani L, Lorini S, Marri S, et al. Role of notch receptors in hematologic malignancies. Cells. 2020;10:16.
   Web of Science ®Google Scholar
• Somnay YR, Yu XM, Lloyd RV, et al. Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosis. Cancer. 2017;123(5):769–782.
   PubMed Web of Science ®Google Scholar
• Nwabo Kamdje AH, Mosna F, Bifari F, et al. Notch-3 and notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood. 2011;118(2):380–389.
   PubMed Web of Science ®Google Scholar
• Jain P, Zhang S, Kanagal-Shamanna R, et al. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 2020;4(6):1038–1050.
   PubMed Web of Science ®Google Scholar
• Gragnani L, Fognani E, De Re V, et al. Notch4 and MHC class II polymorphisms are associated with HCV-related benign and malignant lymphoproliferative diseases. Oncotarget. 2017;8(42):71528–71535.
   PubMedGoogle Scholar
• Martínez N, Almaraz C, Vaqué JP, et al. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia. 2014;28(6):1334–1340.
   PubMed Web of Science ®Google Scholar
• Kiel MJ, Velusamy T, Betz BL, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med. 2012;209(9):1553–1565.
   PubMed Web of Science ®Google Scholar
• Campos-Martín Y, Martínez N, Martínez-López A, et al. Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma. Haematologica. 2017;102(8):e310–e312.
   PubMed Web of Science ®Google Scholar
• Trøen G, Nygaard V, Jenssen TK, et al. Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma. J Mol Diagn. 2004;6(4):297–307.
   PubMed Web of Science ®Google Scholar
• Spina V, Khiabanian H, Messina M, et al. The genetics of nodal marginal zone lymphoma. Blood. 2016;128(10):1362–1373.
   PubMed Web of Science ®Google Scholar
• Shanmugam V, Craig JW, Hilton LK, et al. Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for notch signaling in B-cell tumors. Blood Adv. 2021;5(1):71–83.
   PubMed Web of Science ®Google Scholar
• Arasu A, Balakrishnan P, Velusamy T. RNA sequencing analyses reveal differentially expressed genes and pathways as Notch2 targets in B-cell lymphoma. Oncotarget. 2020;11(48):4527–4540.
   PubMedGoogle Scholar
• Ryan RJH, Petrovic J, Rausch D, et al. Notch-regulated enhancers in B-Cell lymphoma activate MYC and potentiate B-Cell receptor signaling. Blood. 2016;128(22):457–457.
   Web of Science ®Google Scholar
• Hart GT, Wang X, Hogquist KA, et al. Krüppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression. Proc Natl Acad Sci USA. 2011;108(2):716–721.
   PubMed Web of Science ®Google Scholar
• Winkelmann R, Sandrock L, Porstner M, et al. B cell homeostasis and plasma cell homing controlled by Krüppel-like factor 2. Proc Natl Acad Sci USA. 2011;108(2):710–715.
   PubMed Web of Science ®Google Scholar
• Piva R, Deaglio S, Famà R, et al. The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia. 2015;29(2):503–507.
   PubMed Web of Science ®Google Scholar
• Du M-Q. Pathogenesis of splenic marginal zone lymphoma. Pathogenesis. 2015;2(4):11–20.
   Google Scholar
• Clipson A, Wang M, de Leval L, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia. 2015;29(5):1177–1185.
   PubMed Web of Science ®Google Scholar
• Parry M, Rose-Zerilli MJ, Ljungström V, et al. Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res. 2015;21(18):4174–4183.
   PubMed Web of Science ®Google Scholar
• Guidetti F, Bruscaggin A, Frigeni M, et al. Molecular subtypes of splenic marginal zone lymphoma (SMZL) are associated with distinct pathogenic mechanisms and outcomes–interim analysis of the IELSG46 study. Blood. 2018;132(Supplement 1):922–922.
   Google Scholar
• Arribas AJ, Rinaldi A, Mensah AA, et al. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood. 2015;125(12):1922–1931.
   PubMed Web of Science ®Google Scholar
• Takasugi N, Tomita T, Hayashi I, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature. 2003;422(6930):438–441.
   PubMed Web of Science ®Google Scholar
• Colombo M, Galletti S, Garavelli S, et al. Notch signaling deregulation in multiple myeloma: a rational molecular target. Oncotarget. 2015;6(29):26826–26840.
   PubMedGoogle Scholar
• Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual notch receptors. Nature. 2010;464(7291):1052–1057.
   PubMed Web of Science ®Google Scholar
• van Es JH, van Gijn ME, Riccio O, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435(7044):959–963.
   PubMed Web of Science ®Google Scholar
• Real PJ, Ferrando AA. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia. 2009;23(8):1374–1377.
   PubMed Web of Science ®Google Scholar
• Katz JP, Perreault N, Goldstein BG, et al. The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development. 2002;129(11):2619–2628.
   PubMed Web of Science ®Google Scholar
• Samon JB, Castillo-Martin M, Hadler M, et al. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2012;11(7):1565–1575.
   PubMed Web of Science ®Google Scholar
• López-Nieva P, González-Sánchez L, Cobos-Fernández M, et al. More insights on the use of γ-secretase inhibitors in cancer treatment. Oncologist. 2021;26(2):e298–e305.
   PubMed Web of Science ®Google Scholar
• Konishi J, Kawaguchi KS, Vo H, et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007;67(17):8051–8057.
   PubMed Web of Science ®Google Scholar
• Mizugaki H, Sakakibara-Konishi J, Ikezawa Y, et al. γ-Secretase inhibitor enhances antitumour effect of radiation in notch-expressing lung cancer. Br J Cancer. 2012;106(12):1953–1959.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan V, Ansell S, Haug J, et al. MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia. 2012;26(2):340–348.
   PubMed Web of Science ®Google Scholar
• Cullion K, Draheim KM, Hermance N, et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood. 2009;113(24):6172–6181.
   PubMed Web of Science ®Google Scholar
• Shepherd C, Banerjee L, Cheung CW, et al. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia. 2013;27(3):650–660.
   PubMed Web of Science ®Google Scholar
• Knoechel B, Roderick JE, Williamson KE, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014;46(4):364–370.
   PubMed Web of Science ®Google Scholar
• Hayashi I, Takatori S, Urano Y, et al. Neutralization of the γ-secretase activity by monoclonal antibody against extracellular domain of nicastrin. Oncogene. 2012;31(6):787–798.
   PubMed Web of Science ®Google Scholar
• Massard C, Azaro A, Soria JC, et al. First-in-human study of LY3039478, an oral notch signaling inhibitor in advanced or metastatic cancer. Ann Oncol. 2018;29(9):1911–1917.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Martinelli G, Raffoux E, et al. Phase 1 study to evaluate crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. Cancer. 2021;127(3):372–380.
   PubMed Web of Science ®Google Scholar
• Gordon WR, Vardar-Ulu D, Histen G, et al. Structural basis for autoinhibition of notch. Nat Struct Mol Biol. 2007;14(4):295–300.
   PubMed Web of Science ®Google Scholar
• Silkenstedt E, Arenas F, Colom-Sanmartí B, et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-like ligand 4 and is a potential target for specific antibody therapy. J Exp Clin Cancer Res. 2019;38(1):446.
   PubMed Web of Science ®Google Scholar
• Casulo C, Ruan J, Dang NH, et al. Safety and preliminary efficacy results of a phase I first-in-Human study of the novel notch-1 targeting antibody brontictuzumab (OMP-52M51) administered intravenously to patients with hematologic malignancies. Blood. 2016;128:5108–5108.
   Web of Science ®Google Scholar
• Yen W-C, Fischer MM, Axelrod F, et al. Targeting notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res. 2015;21(9):2084–2095.
   PubMed Web of Science ®Google Scholar
• Hu ZI, Bendell JC, Bullock A, et al. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Med. 2019;8(11):5148–5157.
   PubMed Web of Science ®Google Scholar
• Daniel DB, Rudin CM, Hart L, et al. Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Ann Oncol. 2017;28:v540.
   Google Scholar
• Spriano F, Tarantelli C, Arribas A, et al. Abstract B061: targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103. Mol Cancer Ther. 2018;17:B061.
   Web of Science ®Google Scholar
• Garcia JMP, Cortés J, Stathis A, et al. First-in-human phase 1-2A study of CB-103, an oral protein-protein interaction inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies. J Clin Oncol. 2018;36(15_suppl):TPS2619–TPS2619.
   Web of Science ®Google Scholar
• Hubmann R, Hilgarth M, Schnabl S, et al. Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol. 2013;160(5):618–629.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Hu Q, Krishnan N, et al. Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer. Cell Death Dis. 2017;8(12):3217.
   PubMedGoogle Scholar
• Arribas A, Gaudio E, Arcaini L, et al. Targeting the epigenome and the cell signaling as novel therapeutic approaches for splenic marginal zone lymphoma. Blood. 2016;128(22):4186–4186.
   Web of Science ®Google Scholar
• Noy A, de Vos S, Coleman M, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 2020;4(22):5773–5784.
   PubMed Web of Science ®Google Scholar
• Koyama D, Kikuchi J, Hiraoka N, et al. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia. 2014;28(6):1216–1226.
   PubMed Web of Science ®Google Scholar
• Duechler M, Shehata M, Schwarzmeier JD, et al. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia. 2005;19(2):260–267.
   PubMed Web of Science ®Google Scholar
• Troch M, Jonak C, Müllauer L, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009;94(5):738–742.
   PubMed Web of Science ®Google Scholar
• Hill BT, Jagadeesh D, Mejia Garcia AV, et al. Results of a phase I trial of lenalidomide, rituximab (R2) and ixazomib for frontline treatment of high risk follicular and indolent Non-Hodgkin lymphoma. Blood. 2020;136(Supplement 1):1–2.
   PubMedGoogle Scholar
• Takebe N, Miele L, Harris PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12(8):445–464.
   PubMed Web of Science ®Google Scholar
• Ortega-Molina A, Boss IW, Canela A, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. 2015;21(10):1199–1208.
   PubMed Web of Science ®Google Scholar